Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

CDK4/6 Inhibitors Alter HR+ Breast Cancer Paradigm

February 4th 2020

Melissa K. Accordino, MD, MS, discusses the treatment options for patients with hormone receptor-positive, HER2-negative breast cancer.

Risk Status Determines Optimal Treatments in Premenopausal HR+ Breast Cancer

February 4th 2020

Dawn L. Hershman, MD, MS, discusses current treatment considerations in premenopausal women with early-stage, hormone receptor-positive breast cancer.

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer

February 4th 2020

Dawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Despite Advances, Unmet Need Remains in TNBC

February 3rd 2020

Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.

Promising Results Suggest a Larger Role for Immunotherapy in TNBC

February 1st 2020

Although most breast tumors are not immunogenic, evidence indicates that triple-negative breast cancer expressing PD-L1 is a strong candidate for immunotherapy, explained Leisha A. Emens, MD, PhD, in a presentation on recent trials of immunotherapy alone and in combination with anti–PD-1 therapy.

Dr. Ueno on the Residual Cancer Burden and Immunotherapy in Inflammatory Breast Cancer

February 1st 2020

Naoto Ueno, MD, PhD, FACP, discusses residual cancer burden and immunotherapy in inflammatory breast cancer.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

January 31st 2020

Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer.

Dr. Zhu on Mitigating Toxicities of Elective Nodal Irradiation in Breast Cancer

January 22nd 2020

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Dr. Schmid on Activity With Neoadjuvant Pembrolizumab in TNBC

January 21st 2020

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Burris on Ongoing Research With ADCs in TNBC

January 18th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

Charting a New Course in Breast Cancer

January 17th 2020

The 37th Annual Miami Breast Cancer Conference provides practical guidance on cutting-edge developments in the treatment of breast cancer.

Dr. Tauer on the Expansion of Subtyping in Breast Cancer

January 17th 2020

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Role of Radiation Continues to Evolve in Breast Cancer Treatment

January 16th 2020

He James Zhu, MD, PhD, discusses the role of elective nodal irradiation in breast cancer and research efforts that may answer some remaining questions with this modality.

Metastatic TNBC Paradigm Continues to Evolve With Novel Treatments

January 16th 2020

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

January 16th 2020

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Predictive Assays Help Personalize Care in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.

Navigating Frontline Treatment With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

January 14th 2020

Denise Yardley, MD, discusses the implications of CDK4/6 inhibitors in hormone receptor-positive/HER2-negative breast cancer. 